Who is sponsoring NCT07191860?

NCT07191860 is sponsored by Airiver Medical, Inc..

What condition does NCT07191860 study?

NCT07191860 studies Adult Subjects With Symptomatic Benign Airway Obstruction, Adult Benign Central Airway Stenosis, Adult Tracheobronchial Stenosis, Tracheal Stenosis, Central Airway Stenosis, Central Airway Obstruction.

Is NCT07191860 still recruiting?

NCT07191860 is currently not yet recruiting. Last updated 24 March 2026.

Last reviewed 2026-03-24 · How we verify

NCT07191860: OXYGEN-RCT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Central Airway Stenosis

Not yet recruiting NA Last updated 24 March 2026

What this trial tests

NA trial testing The Airiver Pulmonary drug-coated balloon (DCB) dilation in Adult Subjects With Symptomatic Benign Airway Obstruction in 200 participants. Not yet recruiting.

Timeline

1 March 2026

Primary endpoint
1 November 2027

1 November 2030

Quick facts

Lead sponsor	Airiver Medical, Inc.
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	200
Start date	1 March 2026
Primary completion	1 November 2027
Estimated completion	1 November 2030
Sites	1 location across United States

Drugs / interventions tested

The Airiver Pulmonary drug-coated balloon (DCB) dilation
Commercial airway balloon dilation

Conditions studied

Adult Subjects With Symptomatic Benign Airway Obstruction — all drugs for Adult Subjects With Symptomatic Benign Airway Obstruction →
Adult Benign Central Airway Stenosis — all drugs for Adult Benign Central Airway Stenosis →
Adult Tracheobronchial Stenosis — all drugs for Adult Tracheobronchial Stenosis →
Tracheal Stenosis — all drugs for Tracheal Stenosis →

Sponsor

Airiver Medical, Inc. — full company profile →

Who can join

22 and older, any sex, with Adult Subjects With Symptomatic Benign Airway Obstruction or Adult Benign Central Airway Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The OXYGEN-RCT trial is a randomized, controlled, double blinded, prospective, multi-center trial to demonstrate the safety and efficacy in adult benign central airway stenosis. Participates will be in a 1:1 allocation to treatment with the Airiver Pulmonary DCB or standard of care laryngoscopic/bronchoscopic balloon dilation, respectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Airiver Medical, Inc. trials

Trials by the same sponsor.

NCT07290140 — Paclitaxel-Coated Balloon Treatment of Chronic Rhinosinusitis · NA · not yet recruiting
NCT05883462 — Paclitaxel-Coated Nasal Balloon for the Treatment of Recurrent Chronic Rhinosinusitis With or Without Nasal Polyps (FIH) · EARLY_PHASE1 · active not recruiting
NCT05895305 — Paclitaxel-Coated Pulmonary Balloon for the Treatment of Benign Airway Stenosis · EARLY_PHASE1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07191860 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Airiver Medical, Inc.
Last refreshed: 24 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07191860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing